KRAS and cholangiocarcinoma: Molecular alterations within the Ras/Raf/MEK/ERK pathway or the PI3K/AKT/mTOR pathway, such as mutations of KRAS or PIK3CA, are present in all CCA subtypes, where KRAS mutations show the highest frequency in eCCA.